Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

HONG, DAVID SANGHYUN

One or more keywords matched the following items that are connected to HONG, DAVID SANGHYUN

Item Type	Name
Academic Article	Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Academic Article	Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Concept	Mitogen-Activated Protein Kinases
Concept	DNA-Activated Protein Kinase
Concept	Protein Kinase Inhibitors
Concept	Mitogen-Activated Protein Kinase 1
Concept	Mitogen-Activated Protein Kinase Kinases
Concept	Protein Kinases
Concept	AMP-Activated Protein Kinases
Concept	Mitogen-Activated Protein Kinase 3
Academic Article	Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Academic Article	A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
Academic Article	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Academic Article	Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Academic Article	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
Academic Article	Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
Academic Article	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Academic Article	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Academic Article	Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Academic Article	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Academic Article	Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses.
Academic Article	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Academic Article	Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response.
Academic Article	Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Academic Article	PIK3CA mutations in advanced cancers: characteristics and outcomes.
Academic Article	DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor.
Academic Article	MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Academic Article	Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Academic Article	MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
Academic Article	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Academic Article	Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
Academic Article	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
Academic Article	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.
Academic Article	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Academic Article	Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.
Academic Article	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Academic Article	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
Academic Article	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Academic Article	FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Academic Article	Targeting TRK family proteins in cancer.
Academic Article	Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.
Academic Article	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.
Academic Article	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
Academic Article	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Academic Article	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Academic Article	A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Academic Article	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
Academic Article	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Academic Article	Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.
Academic Article	Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Academic Article	Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
Academic Article	Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.
Academic Article	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Academic Article	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Academic Article	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.
Academic Article	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Academic Article	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
Academic Article	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
Academic Article	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Academic Article	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
Academic Article	Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Academic Article	Mechanisms of Resistance to KRASG12C-Targeted Therapy.
Academic Article	Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
Academic Article	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Academic Article	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Academic Article	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Academic Article	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Academic Article	The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.
Academic Article	Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Academic Article	Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Academic Article	Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Academic Article	Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Academic Article	Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.

Search Criteria

Protein Kinases